Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota Ohio State University Comprehensive Cancer Center, Columbus, Ohio Last updated February 2026